Angiotensin Receptor-Neprilysin Inhibitor After Transcatheter Aortic Valve Implantation
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The goal of this trial is to determine whether the initiation of angiotensin
receptor-neprilysin inhibitor (ARNI; sacubitril/valsartan) therapy is safe and effective for
improvement of clinical outcome and reversal of adverse cardiac remodeling among patients who
underwent TAVI as compared with the standard-of-care therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Duk-Woo Park, MD
Collaborators:
CardioVascular Research Foundation, Korea Daewoong Pharmaceutical Co. LTD.